Expected Moves

The Read: Fulcrum's stock fell sharply after in-line earnings and a disappointing pociredir update, then declined further due to cash concerns, briefly rallied after discontinuing pociredir, traded flat amid an equity offering delay and securities investigations, and remained range-bound as earnings met expectations but legal uncertainty persisted.